CA3209581A1 - Inhibiteurs de la phosphoinositide 3 kinase beta et compositions et procedes associes - Google Patents

Inhibiteurs de la phosphoinositide 3 kinase beta et compositions et procedes associes Download PDF

Info

Publication number
CA3209581A1
CA3209581A1 CA3209581A CA3209581A CA3209581A1 CA 3209581 A1 CA3209581 A1 CA 3209581A1 CA 3209581 A CA3209581 A CA 3209581A CA 3209581 A CA3209581 A CA 3209581A CA 3209581 A1 CA3209581 A1 CA 3209581A1
Authority
CA
Canada
Prior art keywords
compound
morpholino
oxo
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3209581A
Other languages
English (en)
Inventor
Jean Zhao
Qi Wang
Xiang Y. Yu
Huimin CHENG
Peiyu Zhang
Zhixiong Lin
Lei Fang
Songling MA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xtalpi Inc
Geode Therapeutics Inc
Original Assignee
Xtalpi Inc
Geode Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xtalpi Inc, Geode Therapeutics Inc filed Critical Xtalpi Inc
Publication of CA3209581A1 publication Critical patent/CA3209581A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne de nouveaux inhibiteurs sélectifs de la phosphoinositide 3 kinase bêta et des compositions pharmaceutiques de ceux-ci, ainsi que des procédés pour leur préparation et leur utilisation, dans la thérapie de diverses maladies et affections, telles que des tumeurs solides.
CA3209581A 2021-02-01 2022-01-25 Inhibiteurs de la phosphoinositide 3 kinase beta et compositions et procedes associes Pending CA3209581A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144287P 2021-02-01 2021-02-01
US63/144,287 2021-02-01
PCT/US2022/013725 WO2022164812A1 (fr) 2021-02-01 2022-01-25 Inhibiteurs de la phosphoinositide 3 kinase bêta et compositions et procédés associés

Publications (1)

Publication Number Publication Date
CA3209581A1 true CA3209581A1 (fr) 2022-08-04

Family

ID=82654889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3209581A Pending CA3209581A1 (fr) 2021-02-01 2022-01-25 Inhibiteurs de la phosphoinositide 3 kinase beta et compositions et procedes associes

Country Status (9)

Country Link
US (1) US20240166617A1 (fr)
EP (1) EP4284375A1 (fr)
JP (1) JP2024508045A (fr)
KR (1) KR20240016938A (fr)
CN (1) CN117615763A (fr)
AU (1) AU2022214080A1 (fr)
CA (1) CA3209581A1 (fr)
IL (1) IL304895A (fr)
WO (1) WO2022164812A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307950A (en) 2021-05-03 2023-12-01 Petra Pharma Corp Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases
BR112023022890A2 (pt) 2021-05-27 2024-01-23 Petra Pharma Corp Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos
WO2024081904A1 (fr) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Méthodes de traitement du cancer
WO2024081889A1 (fr) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Dérivés de 4h-pyrido[1,2-a]pyrimidin-4-one pour le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398163C (fr) * 2000-01-24 2011-02-22 Kinacia Pty Ltd. Composes therapeutiques a substitution morpholino
NZ538420A (en) * 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
WO2022164812A1 (fr) 2022-08-04
IL304895A (en) 2023-10-01
JP2024508045A (ja) 2024-02-21
EP4284375A1 (fr) 2023-12-06
AU2022214080A1 (en) 2023-09-14
US20240166617A1 (en) 2024-05-23
KR20240016938A (ko) 2024-02-06
CN117615763A (zh) 2024-02-27

Similar Documents

Publication Publication Date Title
CA3209581A1 (fr) Inhibiteurs de la phosphoinositide 3 kinase beta et compositions et procedes associes
ES2898698T3 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa Rho (ROCK)
BR112021009880A2 (pt) pirimidina e derivado de heterociclo de nitrogênio de cinco membros, método de preparação para os mesmos e usos médicos dos mesmos
ES2900184T3 (es) Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
CA2984586C (fr) Compose aryl-pyrimidine tricyclique ou a cycle fusionne utilise comme inhibiteur de kinase
TW202122396A (zh) ＫＲａｓ Ｇ１２Ｄ抑制劑
CA2925624A1 (fr) Inhibiteurs de nicotinimide substitues de btk et leur preparation et utilisation dans le traitement du cancer, d'inflammations et des maladies auto-immunes
TW202328124A (zh) 1,4-氧雜氮雜環庚烷衍生物及其用途
KR20130116358A (ko) Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
CN111171049B (zh) 酪氨酸激酶抑制剂及其用途
CA3230071A1 (fr) Benzamides de derives de pyrazolyl-amino-pyrimidinyle, compositions et procedes associes
CA3162253A1 (fr) Inhibiteurs de yeats enl/af9
AU2021256157B2 (en) Tricyclic compounds as EGFR inhibitors
AU2022203737A1 (en) Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors
AU2022214618A1 (en) Cdk2 inhibitors and methods of using the same
CA3155569A1 (fr) Modulateurs polyheterocycliques de sting (stimulateur des genes de l'interferon)
CA3172498A1 (fr) Degradation de la tyrosine kinase de bruton (btk) par conjugaison d'inhibiteurs de btk avec un ligand de ligase e3 et procedes d'utilisation
KR20200090636A (ko) 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CA3142088C (fr) Compose utilise comme inhibiteur de kinase et son application
CA3225285A1 (fr) Inhibiteurs de pi3k.alpha. et leurs procedes d'utilisation
CN114599655B (zh) 咪唑烷酮类化合物及其制备方法与应用
CA3224062A1 (fr) Inhibiteur de proteine ou agent de degradation, composition pharmaceutique le contenant et utilisation pharmaceutique
CA3183668A1 (fr) Urees cycliques d'azetidine
CA3170415A1 (fr) Composes ciblant des proteines de liaison a l'arn ou des proteines modifiant l'arn
CA3218932A1 (fr) Derives de 2,8-dihydropyrazolo[3,4-b]indole destines a etre utilises dans le traitement du cancer